 | Up a level |
Hehlmann, R; Lauseker, M; Saußele, S; Pfirrmann, M; Krause, S; Kolb, H J; Neubauer, A; Hossfeld, D K; Nerl, C; Gratwohl, A; Baerlocher, Gabriela M.; Heim, D; Brümmendorf, T H; Fabarius, A; Haferlach, C; Schlegelberger, B; Müller, M C; Jeromin, S; Proetel, U; Kohlbrenner, K; ... (2017). Assessment of imatinib as first-line treatment of chronic myeloid leukemia: 10-year survival results of the randomized CML study IV and impact of non-CML determinants. Leukemia, 31(11), pp. 2398-2406. Nature Publishing Group 10.1038/leu.2017.253
Horn, H; Ziepert, M; Wartenberg, Martin; Staiger, A M; Barth, T F E; Bernd, H-W; Feller, A C; Klapper, W; Stuhlmann-Laeisz, C; Hummel, M; Stein, H; Lenze, D; Hartmann, S; Hansmann, M-L; Möller, P; Cogliatti, S; Pfreundschuh, M; Trümper, L; Loeffler, M; Glass, B; ... (2015). Different biological risk factors in young poor-prognosis and elderly patients with diffuse large B-cell lymphoma. Leukemia, 29(7), pp. 1564-1570. Nature Publishing Group 10.1038/leu.2015.43
